Recently, it has been reported that inhibition of Hsp90 suppresses lipid synthesis via directly promoting the degradation of sterol regulatory element-binding protein 1 (SREBP1) and SREBP2.77–79 Here, our study proposes an independent mechanism by which the Hsp90 inhibitors function in the treatment of NAFLD and obesity. Here, HSP90AB1 is linked to obesity due to melanocortin 4 receptor deficiency.